Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Vaccines01:30

Cancer Vaccines

380
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
380
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Select Contemporary Statistical Concepts in Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory.

JACC. Heart failure·2026
Same author

Rejoinder to Commentaries on "A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events".

Statistics in medicine·2026
Same author

Kidney Function and Mortality in Mexico: Prospective Study of 130,000 Adults.

Kidney medicine·2026
Same author

Interpretation of Survival Outcomes in Multicancer Early Detection Testing Requires Caution.

JCO precision oncology·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Jul 11, 2025

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis
09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

1.2K

Global Cancer Drug Development-A Report From the 2022 Accelerating Anticancer Agent Development and Validation

Brooke E Wilson1,2, Richard Sullivan3,4, Richard Peto5

  • 1Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, Canada.

JCO Global Oncology
|November 9, 2023
PubMed
Summary

Global cancer survival gains are unequal, with low- and middle-income countries (LMICs) facing access barriers to timely, guideline-concordant care and new anticancer agents. Addressing these disparities requires investment in diagnostics, infrastructure, workforce, and streamlined drug development and regulatory processes.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.5K

Related Experiment Videos

Last Updated: Jul 11, 2025

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis
09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

1.2K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.5K

Area of Science:

  • Oncology
  • Global Health
  • Health Equity

Background:

  • Cancer treatment advancements have improved survival, but benefits are unevenly distributed globally.
  • Patients in low- and middle-income countries (LMICs) face significant barriers to accessing timely and appropriate cancer care.
  • The Accelerating Anticancer Agent Development and Validation workshop highlighted global disparities in cancer drug development and access.

Purpose of the Study:

  • To identify key barriers to global cancer drug development and access, particularly in LMICs.
  • To explore opportunities for improving access to and affordability of cancer treatments worldwide.
  • To emphasize the need for equitable access to high-quality cancer interventions globally.

Main Methods:

  • Discussion and identification of barriers during the Accelerating Anticancer Agent Development and Validation workshop in September 2022.
  • Focus on challenges in Africa and Latin America.
  • Review of potential opportunities and strategies for improvement.

Main Results:

  • Key barriers identified include lack of diagnostic services, insufficient human resources, drug accessibility and affordability issues, weak research infrastructure, and regulatory hurdles.
  • Opportunities include prioritizing investment in diagnostics, health infrastructure, and workforce planning.
  • Streamlined regulatory processes, coordinated drug procurement, and incentivized pricing were discussed as potential solutions.

Conclusions:

  • Equitable access to cancer care requires addressing systemic barriers in LMICs.
  • Strategic investments in infrastructure, diagnostics, workforce, and regulatory processes are crucial.
  • Continued advocacy and development of relevant clinical trials are essential for global cancer equity.